Avacta Group Plc (AIM:AVCT)
63.77
-0.43 (-0.67%)
Oct 15, 2026, 2:07 PM GMT
Avacta Group Revenue
Avacta Group had revenue of 56.00K GBP in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to 113.00K. In the year 2025, Avacta Group had annual revenue of 113.00K. That makes Avacta Group the 45,708th largest company in the world by revenue and 922nd in the United Kingdom.
Revenue
113.00K
Revenue Growth
n/a
P/S Ratio
2,765.64
Revenue / Employee
1.40K
Employees
81
Market Cap
310.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 113.00K | - | - |
| Dec 31, 2024 | 113.00K | -2.74M | -96.04% |
| Dec 31, 2023 | 2.85M | -6.80M | -70.47% |
| Dec 31, 2022 | 9.65M | 6.71M | 228.22% |
| Dec 31, 2021 | 2.94M | 797.00K | 37.17% |
| Dec 31, 2020 | 2.14M | -619.00K | -22.40% |
| Jul 31, 2018 | 2.76M | 28.00K | 1.02% |
| Jul 31, 2017 | 2.74M | 570.00K | 26.33% |
| Jul 31, 2016 | 2.17M | 352.00K | 19.42% |
| Jul 31, 2015 | 1.81M | 195.00K | 12.05% |
| Jul 31, 2014 | 1.62M | -1.08M | -40.07% |
| Jul 31, 2013 | 2.70M | -430.00K | -13.74% |
| Jul 31, 2012 | 3.13M | 685.00K | 28.02% |
| Jul 31, 2011 | 2.45M | 378.00K | 18.29% |
| Jul 31, 2010 | 2.07M | 1.12M | 118.96% |
| Jul 31, 2009 | 944.00K | 478.00K | 102.58% |
| Jul 31, 2008 | 466.00K | 254.00K | 119.81% |
| Jul 31, 2007 | 212.00K | 15.00K | 7.61% |
| Jul 31, 2006 | 197.00K | 193.00K | 4,825.00% |
| Apr 30, 2006 | 4.00K | -309.00K | -98.72% |
| Apr 30, 2005 | 313.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Genus | 658.10M |
| Oxford Nanopore Technologies | 235.00M |
| Oxford Biomedica | 175.36M |
| Bioventix | 12.54M |
| PureTech Health | 4.80M |
| Scancell Holdings | 4.71M |
| Ondine Biomedical | 1.53M |
| Faron Pharmaceuticals Oy | 1.14M |
Avacta Group News
- 14 days ago - Avacta H1 Loss Widens As AVA6103 Advances Toward 2027 Data - Nasdaq
- 15 days ago - Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update - Finanz Nachrichten
- 15 days ago - Avacta Group Quarterly report: H1 2026 - Filings
- 4 weeks ago - Avacta Achieves Clinical Proof Of Mechanism For AVA6103 In Phase 1 FOCUS-01 Trial - Nasdaq
- 4 weeks ago - Avacta Group PLC: Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial - Finanz Nachrichten
- 4 weeks ago - Avacta Appoints Blom To Board As Audit Committee Chair; Advances Pre|CISION Platform - Nasdaq
- 6 weeks ago - Avacta Group Slides: Corporate presentation - Filings
- 3 months ago - Avacta Group Slides: FY 2026 - Filings